The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Causality assessment can be problematic in patients on concomitant infliximab and methotrexate or azathioprine

Publications

Rofaiel R, Kohli S, Mura M, Hosseini-Moghaddam SM

A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule.

BMJ case reports. 2017;2017

Schoehl J, Mechie NC, Schwoerer H, Moerer O, Quintel M, Buck C, Ellenrieder V, Neesse A, Amanzada A

Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease.

Case reports in gastroenterology. 2016;10(3):574-580

Bale J, Chee P

Acute alveolitis following infliximab therapy for psoriasis.

The Australasian journal of dermatology. 2013;54(1):61-3